OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection

OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients withClostridium difficileInfection In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile In Vitro Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of Staphylococcus spp. and Enterococcus spp Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile -Associated Diarrhea and Prevention of Disease Recurrence in Hamsters In Vitro Activities of 15 Antimicrobial Agents against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983 to 2004 Effects of Inoculum, pH, and Cations on the In Vitro Activity of Fidaxomicin (OPT-80, PAR-101) against Clostridium difficile In Vitro Activities of Telavancin and Six Comparator Agents against Anaerobic Bacterial Isolates Micrococcin P2 Targets Clostridioides difficile Salicylanilide Analog Minimizes Relapse of Clostridioides difficile Infection in Mice